QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
Austin, TX, April 26, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB:QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and other diseases, announced today that the European Patent Office (EPO) has allowed a key patent that protects the use of “lower specific activity” Samarium-153 in conjunction with the treatment of bone cancer in children and adults.
Related news for (QSAM)
- QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
- QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
- QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
- QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
- QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center